Lüthje Lars, Renner Bernd, Kessels Roger, Vollmann Dirk, Raupach Tobias, Gerritse Bart, Tasci Selcuk, Schwab Jörg O, Zabel Markus, Zenker Dieter, Schott Peter, Hasenfuss Gerd, Unterberg-Buchwald Christina, Andreas Stefan
Kardiologie und Pneumologie, Georg-August-Universität, Göttingen, Germany.
Eur J Heart Fail. 2009 Mar;11(3):273-80. doi: 10.1093/eurjhf/hfn042. Epub 2009 Jan 12.
The combined therapeutic impact of atrial overdrive pacing (AOP) and cardiac resynchronization therapy (CRT) on central sleep apnoea (CSA) in chronic heart failure (CHF) so far has not been investigated. We aimed to evaluate the effect of CRT alone and CRT + AOP on CSA in CHF patients and to compare the influence of CRT on CHF between CSA positive and CSA negative patients.
Thirty patients with CRT indication underwent full night polysomnography, echocardiography, exercise testing, and neurohumoral evaluation before and 3 months after CRT implantation. In CSA positive patients (60%), two additional sleep studies were conducted after 3 months of CRT, with CRT alone or CRT + AOP, in random order. Cardiac resynchronization therapy resulted in significant improvements of NYHA class, left ventricular ejection fraction, N-terminal pro-brain natriuretic peptide, VO(2)max, and quality of life irrespective of the presence of CSA. Cardiac resynchronization therapy also reduced the central apnoea-hypopnoea index (AHI) (33.6 +/- 14.3 vs. 23.8 +/- 16.9 h(-1); P < 0.01) and central apnoea index (17.3 +/- 14.1 vs. 10.9 +/- 13.9 h(-1); P < 0.01) without altering sleep stages. Cardiac resynchronization therapy with atrial overdrive pacing resulted in a small but significant additional decrease of the central AHI (23.8 +/- 16.9 vs. 21.5 +/- 16.9 h(-1); P < 0.01).
In this study, CRT significantly improved CSA without altering sleep stages. Cardiac resynchronization therapy with atrial overdrive pacing resulted in a significant but minor additional improvement of CSA. Positive effects of CRT were irrespective of the presence of CSA.
迄今为止,心房超速起搏(AOP)与心脏再同步治疗(CRT)联合治疗对慢性心力衰竭(CHF)患者中枢性睡眠呼吸暂停(CSA)的综合疗效尚未得到研究。我们旨在评估单纯CRT以及CRT+AOP对CHF患者CSA的影响,并比较CSA阳性和CSA阴性患者中CRT对CHF的影响。
30例有CRT指征的患者在CRT植入前及植入后3个月接受了整夜多导睡眠图、超声心动图、运动试验及神经体液评估。在CSA阳性患者(60%)中,CRT治疗3个月后,随机顺序进行另外两项睡眠研究,分别为单纯CRT或CRT+AOP。无论是否存在CSA,心脏再同步治疗均使纽约心脏协会(NYHA)心功能分级、左心室射血分数、N末端脑钠肽前体、最大摄氧量(VO₂max)及生活质量得到显著改善。心脏再同步治疗还降低了中枢性呼吸暂停低通气指数(AHI)(33.6±14.3比23.8±16.9次/小时;P<0.01)和中枢性呼吸暂停指数(17.3±(此处原文似乎有误,推测可能是14.1)比10.9±13.9次/小时;P<0.01),且未改变睡眠阶段。心房超速起搏的心脏再同步治疗使中枢性AHI有小幅但显著的额外下降(23.8±16.9比21.5±16.9次/小时;P<0.01)。
在本研究中,CRT显著改善了CSA且未改变睡眠阶段。心房超速起搏的心脏再同步治疗使CSA有显著但较小的额外改善。CRT的积极作用与CSA的存在无关。